The Chronic Sialorrhea Market is gaining increasing attention as healthcare providers focus on better management of excessive drooling associated with neurological disorders such as Parkinson’s disease, cerebral palsy, and amyotrophic lateral sclerosis. Chronic sialorrhea occurs when patients cannot effectively control saliva production or swallowing. The Chronic Sialorrhea Market size was valued at USD 798.53 Million in 2025 and is projected to grow at a CAGR of 4.91% from 2026 to 2035, reaching approximately USD 1,289.62 Million by 2035. Market expansion is largely driven by the rising prevalence of neurological conditions, improved treatment options, and growing awareness among healthcare professionals and patients.

What Is the Current Size and Share of the Chronic Sialorrhea Market?

The Chronic Sialorrhea Market size and share are expanding steadily due to the increasing use of pharmacological and minimally invasive treatment methods. Pharmacological treatments such as anticholinergic medications remain widely used to reduce saliva production. Common drugs include glycopyrrolate, scopolamine, tropicamide, and other medications designed to control symptoms. Additionally, botulinum toxin therapies, including IncobotulinumtoxinA (Xeomin) and RimabotulinumtoxinB (Myobloc), hold a significant market share because they offer targeted and long-lasting symptom relief with fewer systemic side effects.

How Is the Chronic Sialorrhea Market Segmented?

The Chronic Sialorrhea Market is segmented by type, treatment, route of administration, distribution channel, and region. Based on type, the market includes anterior chronic sialorrhea and posterior chronic sialorrhea. Treatment segments consist of pharmacological therapies, botulinum toxin treatments, and invasive procedures such as surgery and radiotherapy. Routes of administration include oral, sublingual, transdermal, intranasal, intramuscular, and other methods. Distribution channels primarily include retail pharmacies and hospital pharmacies, which ensure medication availability for patients requiring long-term management.

Request sample report Explore

Which Regions and Companies Are Leading the Chronic Sialorrhea Market?

The Chronic Sialorrhea Market growth is led by regions such as the United States, EU-4 and the United Kingdom, Japan, and India, where healthcare systems are investing in neurological care and advanced therapeutics. Increasing research activity and improved patient awareness are also contributing to regional market expansion. Major companies operating in the market include US WorldMeds, LLC, Merz Pharmaceuticals, LLC, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, GSK Plc, Bayer AG, McKesson Medical-Surgical Inc., Aurobindo Pharma Ltd., and Hikma Pharmaceuticals PLC. These companies focus on innovative therapies, clinical research, and strategic collaborations to strengthen their market position.